-- 
Amsterdam Commodities, UCB, Lanschot: Benelux Equity Preview

-- B y   J o h n   M a r t e n s   a n d   J u r j e n   v a n   d e   P o l
-- 
2011-03-18T04:00:02Z

-- http://www.bloomberg.com/news/2011-03-18/amsterdam-commodities-ucb-lanschot-benelux-equity-preview.html
The following companies may have
unusual price changes in Benelux markets. Stock symbols are in
parentheses, and prices are from the previous close.  The  AEX-Index (AEX)  in Amsterdam advanced 6.06, or 1.8 percent,
to 349.26.  Belgium ’s Bel20 Index rose 34.75, or 1.4 percent, to
2,557.71. Luxembourg’s LuxX Index gained 1 percent to 1,413.83.  Dutch stocks:    Amsterdam Commodities NV (ACOMO)  : The world’s largest
trader of spices said full-year net income rose 47 percent to
15.5 million euros ($21.7 million). Amsterdam Commodities fell
1.9 percent to 10.35 euros.    Van Lanschot NV (LANS)  : The oldest independent Dutch
bank may report second-half profit excluding some items of 43
million euros, according to the average of three analyst
estimates compiled by Bloomberg. Van Lanschot climbed 3.4
percent to 31.55 euros.  Belgian stocks:  International Brachytherapy SA (IBT BB): Eckert & Ziegler
AG (EUZ GY), the majority owner of the Belgian maker of tumor-
fighting implants, said it has made an approach to buy
Theragenics Corp. (TGX US), either directly or through its
Belgian unit, for about $74 million in cash. Theragenics’s board
rejected the $2.20-a-share offer, Eckert & Ziegler said.  International Brachytherapy (IBT)  climbed 2.2 percent to 2.85 euros.    TiGenix NV (TIG)  : The developer of treatments for
damaged joints that plans to merge with Cellerix SA posted a
full-year net loss of 15.7 million euros and said it had 5.6
million euros of cash and short-term investments left on Dec.
31. TiGenix was unchanged at 1.31 euros.    UCB SA (UCB)  : The maker of the Cimzia arthritis medicine
failed to win the backing of advisers to the European Medicines
Agency to market Xyrem as a treatment for fibromyalgia,
associated with chronic muscle pain and fatigue, in  Europe . UCB
rose 1.2 percent to 25.96 euros.  To contact the reporters on this story:
John Martens in Brussels at 
 jmartens1@bloomberg.net ;
Jurjen van de Pol in Amsterdam at 
 jvandepol@bloomberg.net   To contact the editors responsible for this story:
Angela Cullen at   acullen8@bloomberg.net ;
Craig Stirling at   cstirling1@bloomberg.net . 